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Avascular necrosis after oral corticosteroids in
otolaryngology: Case report and review of the literature
Patrick Kennedy, Jr., B.A.,1 Ahmed Bassiouni, M.B.B.S.,2 Alkis Psaltis, M.B.B.S.,3
Jastin Antisdel, M.D.,4 and Joseph Brunworth, M.D.4
ABSTRACT
Objective: In this report, we present a rare case of avascular necrosis (AVN) in an otherwise healthy 42-year-old male
patient treated with low dose oral corticosteroids for his bronchitis. A systematic review of the literature related to AVN and
corticosteroids was performed.
Case Report: Forty-two-year-old male with no underlying conditions predisposing him to AVN who had been treated
four years before for chronic bronchitis with two courses of oral prednisone therapy presented with bilateral AVN of the
hips.
Methods: An OVID database search of the terms “low total dose,” “corticosteroids,” and “avascular necrosis” was
performed. Two PubMed searches of various permutations of “low-dose,” “corticosteroids,” “avascular necrosis,” and
“osteonecrosis” were also performed. Results were then narrowed to relevant articles.
Results: Median total dose of oral corticosteroids in patients with AVN in reviewed articles was 981 mg, with lowest
reported association at 105 mg. Median duration of therapy was 16 days with shortest course of six days.
Conclusion: There is emerging data linking AVN with corticosteroid doses previously thought to be safe. After reviewing
the relevant literature, it is our consensus to inform all patients regarding AVN before oral corticosteroid use.
(Allergy Rhinol 7:e50–e54, 2016; doi: 10.2500/ar.2016.7.0142)
Avascular necrosis (AVN) is a rare but serious dis-order in which interruption of blood supply re-
sults in bone tissue death and destruction of the artic-
ular surface of joints, most commonly the hip. AVN
carries high morbidity accounting for an estimated
10% of all United States hip arthroplasties,1 whereas
AVN with subsequent fracture of the femoral head
carries an in-hospital mortality rate of 1%–10%2–4 and
a one year mortality rate ranging from 12% to 37%,5,6
depending on patient age and sex. The male-to-female
ratio of AVN is approximately 4:1, with mean age of
onset occurring between the fourth and fifth decade.2
Although AVN is strongly associated with several risk
factors, including underlying rheumatologic condi-
tions such as systemic lupus erythematosis, bisphos-
phonate use, radiation exposure, and heavy alcohol
consumption,7,8 systemic corticosteroid use has been
implicated in almost one-third of all cases of AVN.1,9,10
Several studies have investigated a proposed dose-
dependent relationship between corticosteroid use and
AVN with varied results. Cumulative total dose rela-
tionships have been reported to range from 440 to 9000
mg with relative risks (RRs) of AVN of 6 and 8.8 for the
respective doses.11–13 Controversy exists among stud-
ies examining duration of corticosteroid treatment. Al-
though some have shown that AVN can occur with
therapy ranging from 2813 to 700 days,11 others found
no risk associated with long-term treatment with cor-
ticosteroids.14,15
CASE REPORT
Previous studies looking at cumulative total dose
relationships between oral steroids and AVN often
fail to differentiate between patients receiving solely
oral corticosteroids versus those who have also been
administered intravenous (IV) corticosteroids. In this
case report, we discuss a 42-year-old male who sus-
tained AVN of his right hip after low total dose
corticosteroid treatment. This patient presented to
our department with worsening of his right hip pain,
which had been present for four years. There was no
history of trauma. The patient had sustained a lower
back injury three years before, and his worsening hip
pain had previously been attributed to this. His past
medical history was significant for an umbilical her-
nia and asthma controlled with an albuterol inhaler
as required; it was negative for any history of auto-
immune disease. Family history was significant for
hypertension in both parents and negative for auto-
immune diseases. He had a 15 pack-year smoking
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history and no history of alcohol abuse. Upon further
investigation, it was found that he had been treated
for a chronic bronchitis exacerbation four years be-
fore with two short courses of oral prednisone ther-
apy, which included: 40 mg per day for seven days,
20 mg per day for two days, and 10 mg per day for
two days followed by a two week break. His second
course consisted of 60 mg per day for four days, 40
mg per day for four days, 20 mg per day for four
days, and 10 mg per day for four days. Total dura-
tion of therapy was 27 days, and total cumulative
dose of prednisone was 860 mg.
Physical exam revealed reduced range of passive and
active motion of the right hip. Bilateral plain films and
magnetic resonance imaging of the hips were obtained
due to concern of AVN. Final impression of the mag-
netic resonance imaging was read as bilateral AVN of
the hip, with the right hip having had a more acute
phase with marrow involvement than the left.
One month later, he elected to undergo right hip
replacement. The hip arthroplasty was performed
with a femoral prosthesis without complication. He
was discharged four days postoperatively to begin
physical therapy and rehabilitation of the joint. One
year after the procedure, he was able to walk with-
out any detectable limp and regained nearly full
range of pain-free motion in right hip, whereas the
left hip never progressed to the point of needing
replacement.
METHODS
A search of the PubMed and OVID databases for
English language publications between 2000 and 2015
was performed (Fig. 1). OVID key search terms in-
cluded “low total dose” and “corticosteroids” or “low
total dose steroids” and “avascular necrosis.” PubMed
search terms included “low dose” and “corticoste-
roids” or “low dose” and “steroids” and “avascular
necrosis.” Articles published before this date, not of the
English language, lacking in detail regarding duration
and dosing of oral steroid or relating to IV steroid
administration only were excluded. Data collected and
analyzed included demographic data, documented
risk factors for AVN, routes of steroid administration,
cumulative steroid dose, total duration of therapy, and
incidence of AVN. For the purposes of this review,
total dose and cumulative dose refer to total amounts
of corticosteroids prescribed for a single treatment ep-
isode spanning less than three months. None of the
literature found in our review had access to a central-
ized pharmacologic reporting system for patients ana-
Figure 1. Flow chart explanation of
systematic literature review.
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lyzed, therefore “life-time” cumulative dose of cortico-
steroids and its relation to AVN would be impossible
to quantify.
RESULTS
Forty-six articles were identified on the initial data-
base search. Five full-length articles met the inclusion
criteria for this study. These articles consisted of one
retrospective cohort study,16 one case-control study,13
and three case reports.17–19 A total of 10,825 total in-
stances of AVN of the hip were reported across these
five articles, with an overwhelming majority occurring
in the Dilisio study.16 A total of 123/10,825 cases of
AVN of the hip were associated with oral corticoste-
roid use (1.14%), and one case was associated with
inhaled corticosteroid use. Of the total instances of
AVN found in our review of the literature, 5705/10,825
were male (52.7%) and 5120/10,825 were female
(47.3%). The median reported age for AVN secondary
to oral corticosteroid use was 51.5 years with a range of
29–69 years. The indications for corticosteroid use
were reported in four articles for a total of 14 patients
and included asthma 4/14 (28.6%) 3/14 (21.4%) for
autoimmune diseases, 2/14 (14.3%) chronic bronchitis,
and 1/14 (7.1%) each for migraine with aura, postche-
motherapy nausea, cerebral edema, gout, and acute
transplant rejection. Durations of corticosteroid ther-
apy reported in the articles included: 6 days, 11 days,
21 days, 44 days, and 20 years. Excluding the 20-year
case report, median duration of oral corticosteroid
therapy associated with AVN in our literature review
was 16 days. Reported cumulative doses of oral or
inhaled corticosteroids associated with subsequent de-
velopment of AVN (converted to prednisone equiva-
lent) ranged from 105 to 1160 mg, with median cumu-
lative dose of 981 mg.
DISCUSSION
The patient in our case report fits many of the de-
mographic characteristics of AVN (male, 40–50 years
old), although his lack of underlying comorbidities or
chronic medications and the delayed presentation of
AVN make this an unusual case. Our patient’s total
cumulative dose of 860 mg of prednisone coincides
with other high-risk dose ranges in the literature13
which fall between 440 and 1290 mg, although it con-
trasts with more recent claims suggesting more than
1000 mg as the threshold for concern.20 One possible
limitation in interpreting the study by Bauer et al.13 that
produced the 440- to 1290-mg dose range is its exclu-
sion of any patient who presented with AVN more
than three years after receiving oral prednisone ther-
apy, as this would have excluded our patient who was
diagnosed with AVN more than four years after his
courses of oral prednisone. Among the two studies
which calculated RR of AVN among their patients with
documented corticosteroid use, both found increased
risk of AVN with oral corticosteroids compared with
controls.13,16 Dilisio, whose study involved patients
with isolated oral corticosteroid exposure, found a RR
of 1.378 for AVN (95% confidence interval [CI], 1.069–
1.697) at total doses as low as 105 mg (prednisone
equivalent), and RR of 3.704 (95% CI, 2.806–4.602) for
patients who had received at least 210 mg (prednisone
equivalent). Bauer’s nested case-control reported RR 0
(95% CI, 0–5) for total doses of oral prednisone less
than 430 mg, RR 6 (95% CI, 1–43) for total doses
between 440 and 1290 mg, and an increased but unde-
fined RR for total doses more than 1290 mg. Our case
report highlights an important concern for those gen-
erally considered low risk for AVN as prescriptive
practices become increasingly dependent on the use of
prednisone for a multitude of diseases spanning each
subspecialty within otolaryngology.
The use of oral corticosteroids in the United States
has been increasing over the past 15 years, with pre-
scriptions for oral prednisone accounting for a majority
of the increase. A review of national databases col-
lected by the Centers for Disease Control and Preven-
tion cited a 13% increase in prescriptions of oral pred-
nisone across all specialties for adults from 2000 to
2009, whereas the increase in prescriptions for children
during the same time period was even higher at 38%.21
With respect to otolaryngology, current medical man-
agement of rhinosinusitis, sudden sensorineural hear-
ing loss (SSHL), and many other diseases rely heavily
on oral corticosteroid therapy as a key treatment mo-
dality for both children and adults.22,23 Recent attempts
to compare prescriptive practices of corticosteroids be-
tween primary care physicians and otolaryngologists
are sparse, but initial reports indicate significantly
higher rates of corticosteroid prescriptions by otolar-
yngologists (Fig. 2).24–26 In addition to this variability
in practice trends, it appears that for certain conditions
such as SSHL, there is significant variability within the
field of otolaryngology itself, with otologists choosing
corticosteroid therapy at the highest frequency.27
Limitations in our study include a sparsity of litera-
ture analyzing isolated use of oral corticosteroids, with
the clear majority having been published before 2000.
Only one of the articles included in our review specif-
ically looked at patients who had solely received oral
corticosteroids,16 with three of the five articles, includ-
ing patient populations who had either unknown pre-
vious histories of IV corticosteroid use or at least one
documented instance of IV corticosteroid administra-
tion. We included one case report that involved iso-
lated use of inhaled corticosteroids.17 Furthermore,
several patients from the case reports had complicated
clinical pictures due to underlying malignancy and
concurrent use of chemotherapy with corticosteroids,18
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remote past medical history of hip fracture,17 or lack of
data collected on comorbidities,16 making it difficult to
isolate corticosteroids as the sole risk factor for AVN.
Although it is difficult to assess the motivations be-
hind increasing oral corticosteroid use in the field of
otolaryngology as a whole, recent surveys have raised
concerns regarding practitioners’ reliance on anecdotal
experience as opposed to evidence provided in the
academic literature. A recent survey of factors affecting
prescriptions of corticosteroids revealed that 74% of
respondents cited previous experience and 59% cited
familiarity as very important factors, with less than
50% of respondents citing academic literature, side
effect profile, or empiric data as even moderately im-
portant factors influencing their choice of corticoste-
roid use.28 This is particularly concerning as a recent
review of medical malpractice and corticosteroid use
found that 65% of allegations cited negligence or im-
proper use of corticosteroids as reason for filing, with
another 36% citing lack of informed consent. The most
common complication of corticosteroid use cited by
plaintiffs was AVN, affecting 39% of plaintiffs after
corticosteroid therapy.29 Recent systematic reviews of
oral corticosteroid monotherapy in acute sinusitis,
SSHL, and chronic rhinosinusitis without nasal polyps
have questioned its utility and found its value to be
unclear, placing its position as standard therapy in
these conditions in jeopardy.30–32 Regarding informed
consent and oral corticosteroid use, a recent random-
ized controlled trial found that patients had great dif-
ficulty recalling discussions of adverse risks of predni-
sone use as little as two weeks after the discussion took
place, with median number of adverse risks recalled
ranging from 1 to 2.33 The current state of the literature
regarding oral corticosteroid use in common otolaryn-
gologic problems remains unclear, the use of cortico-
steroids among practitioners remains highly variable,
and practitioners may be overestimating patients’ abil-
ity to recall the myriad of risks associated with corti-
costeroid use.
CONCLUSION
Ultimately, the rarity of development of AVN from
oral corticosteroids limits our understanding of this
disease and its risks factors to case reports and a few
cohort studies. The risk of AVN from high cumulative
doses of IV corticosteroids is more established and
therefore warrants informed consent when appropri-
ate. Due to the paucity of literature on the subject, more
research is needed regarding the isolated use of oral
corticosteroids and risk of AVN. Emerging reports of
AVN after total doses of corticosteroids previously
thought safe have necessitated a need for complete con-
sensus among otolaryngologists regarding informed con-
sent of AVN before oral corticosteroid use. After a sys-
tematic review of the literature, we advocate that a
discussion about AVN should be included in every
patient encounter before a course of oral corticoste-
roids, highlighting both the rarity and severity of such
Figure 2. Comparison of otolaryngol-
ogist versus primary care physician
corticosteroid use in SSHL.
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a complication. Patients undergoing high dose oral
steroids, even at total doses less than 1000 mg, who
have other potential risk factors would especially ben-
efit from this discussion. This includes: underlying
high-risk medical conditions for AVN (systemic lupus
erythematosis, bisphosphonate therapy, alcoholism,
etc.), male gender in their forties or fifties, or any pre-
vious treatment with corticosteroids.
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